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Abstract
Background: In response to viral infection, bronchial epithelial cells increase inflammatory cytokine release to activate the
immune response and curtail viral replication. In atopic asthma, enhanced expression of Th2 cytokines is observed and we
postulated that Th2 cytokines may augment the effects of rhinovirus-induced inflammation.
Methods: Primary bronchial epithelial cell cultures from pediatric subjects were treated with Th2 cytokines for 24 h before
infection with RV16. Release of IL-8, IP-10 and GM-CSF was measured by ELISA. Infection was quantified using RTqPCR and
TCID50. Phosphatidyl inositol 3-kinase (PI3K) and P38 mitogen activated protein kinase (MAPK) inhibitors and
dexamethasone were used to investigate differences in signaling pathways.
Results: The presence of Th2 cytokines did not affect RV replication or viral titre, yet there was a synergistic increase in IP-10
release from virally infected cells in the presence of Th2 cytokines. Release of IL-8 and GM-CSF was also augmented. IP-10
release was blocked by a PI3K inhibitor and IL-8 by dexamethasone.
Conclusion: Th2 cytokines increase release of inflammatory cytokines in the presence of rhinovirus infection. This increase is
independent of effects of virus replication. Inhibition of the PI3K pathway inhibits IP-10 expression.
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Introduction
Asthma is a complex respiratory disease characterized by
variable airflow obstruction, bronchial hyper-responsiveness and
airway inflammation. In atopic asthma, the Th2 type cytokines
interleukin (IL)-13 and IL-4 [1] are key players in allergic
responses, playing a pivotal role in inflammatory and remodelling
aspects of asthma pathogenesis [2,3]. Th2 cytokines can impair
immune responses to viral infections. It has been shown that adults
with a ‘less atopic phenotype’ have a greater ability to clear human
rhinovirus (RV) compared to atopic adults [4,5].
Although atopic asthma is the more dominant form of asthma
during school years and into young adulthood [6–8], exacerbation
of asthma has been strongly linked to respiratory infection alone,
with 44% to 80% of childhood asthma exacerbations being
triggered by RV infection [9]. RV is the most common pathogen
associated with asthma exacerbations in children [10]. Further-
more, a combination of sensitization, high exposure to one or
more allergens, and viral detection significantly increases the risk of
hospitalization for asthma [11,12].
The mechanisms behind the association of atopy and virus co-
morbidity are as yet, unclear. Some studies have provided
evidence that Th2 cytokines and viral pathogen associated
molecular patterns (PAMPs) trigger release of the Th2 polarizing
cytokine thymic stromal lymphopoietin [13], whilst other studies
have shown that the epithelial effects of Th2-associated cytokines,
such as IL13 and IL4, are dominant over the effects of the Th1-
associated cytokines such as interferon-gamma [14]. Like allergen
and RV, IL-13 and IL-4 have been shown to enhance expression
of ICAM-1 [14,15], the cellular receptor for major group RVs.
Th2 cytokines have the potential to facilitate entry of major group
RV into airway cells of atopic subjects and to favour migration and
activation of immune effector cells into the airway. This study uses
epithelial monolayer cultures from a non asthmatic pediatric
population to investigate whether the presence of Th2 cytokines
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modulates virus-induced inflammation; we also examine the ability
of signaling pathway inhibitors to suppress these responses.
Methods
Ethics statement
Ethical approval was given by the Southampton and South
West Hampshire Research Ethics Committee (07/Q1704/21).
Parents of participants provided written informed consent.
Procedures, including consent, was approved by the ethics
committee.
Primary Cell culture
Bronchial brushings were obtained by fibreoptic bronchoscopy
from pediatric subjects, not diagnosed with asthma, following
current guidelines [16]. Subjects were recruited when attending
hospital for clinically indicated bronchoscopy or other planned
surgical procedure under a general anaesthetic. The subject group
comprised 8 males (mean age 7.3 years; range 2–15 years), and 7
females (mean age 8.4 years; range 1–15 years). Details of patient
phenotypes are in table 1. Brushings were processed for primary
bronchial epithelial cell (pBEC) culture in Bronchial Epithelial
Growth Medium (BEGM) (Lonza, Wokingham, United King-
dom,) as previously described [17]. Pediatric pBECs (ppBECs)
were plated onto collagen coated (30 mg/ml PureCol, Inamed
Biomaterials, Fremont, USA) 12-well plates (Nunc, Fisher
Scientific, Loughborough, United Kingdom), at passage 2. For
experiments minimal medium, BEBM, was used.
Virus culture
RV16 (a gift from Professor Sebastian L. Johnston, Imperial
College, London) was amplified as previously described [18]. Virus
strain was confirmed by qPCR (Primer Design, Southampton,
UK) and infectivity determined with HeLa titration assay and
50% tissue culture infective dose (TCID50)/ml.: Ultra violet
treated virus controls (UV) were obtained by irradiating live virus
stocks (1200 mJ/cm2 on ice for 50 min). Inactivation of virus was
confirmed by TCID50.
Infection of cells with RV
pBECs were infected with RV16 (Dose: 16106 TCID50 units/
106 cells) for 1 hour at room temperature. Cells were washed to
remove residual viral particles and the cultures replenished with
BEBM. Different multiplicities of infection (MOIs) were not tested
due to limitations in sample availability. Based on previous
experience we chose a moderate dose of virus for infection. RV16
was chosen since it has minimal cytotoxic effects, as seen in figure
S1.
Cytokine treatments
Cultures were pretreated with 10 ng/ml [19] of IL-13, IL-4 or
both, for 24 h prior to infection. Cytokines were replenished with
BEBM after washing, post-infection.
Controls of UV irradiated RV16, medium alone and Th2 only
controls were included in all experiments.
Inhibitor treatments
Inhibitors were added to cultures 30 minutes before infection
with RV16 and were refreshed after infection. Inhibitors of PI3K
(LY294002, Calbiochem, Merck Millipore, UK) and p38
(SB03580, Sigma-Aldrich, Dorset, UK) were used at 10 mM,
and dexamethasone (Sigma-Aldrich, Dorset, UK) at 1 mM.
Vehicle control (DMSO) was used in all experiments.
Extraction of total RNA and mRNA quantification
Cells were harvested into TRIzol reagent (Invitrogen,UK) and
total RNA was isolated using standard protocols. RNA (1 mg) was
reverse-transcribed using Precision reverse transcription kit
(Primer Design, Southampton, UK) according to the manufac-
turer’s instructions. cDNA was amplified by PCR using Perfect
Probe or Double Dye assays (Primer Design, Southampton,
UK). Expression levels of cytokines were calculated relative to
Table 1. Summary of clinical and physiological characteristics of subjects studied.
Subject Age (yrs) Gender Indication/operation
1 1 F Bronchoscopy - recurrent chest symptoms & intermittent stridor
2 11 M Bronchoscopy - recurrent severe croup
3 3 M Bronchoscopy - recurrent croup and stridor
4 5 M Bronchsocopy- recurrent cough, prematurity, tracheomalacia
5 3 M Bronchoscopy - tracheomalacia
6 1 F Bronchoscopy - recurrent chronic cough
7 2 M Bronchoscopy - tracheomalacia
8 6 M Adenoidectomy and tonsillectomy, gromit insertion
9 14 M Surgery for nasal septum deviation
10 10 F Dental procedure
11 12 F Dental procedure
12 15 F Dental procedure
13 7 F Dental procedure
14 13 F Dental procedure
15 15 M Dental procedure
Subjects were recruited when attending hospital for clinically indicated bronchoscopy or other planned surgical procedure under a general anaesthetic. Bronchial
brushings were obtained by fibreoptic bronchoscopy from pediatric subjects not diagnosed with asthma following current guidelines [16]. Mean age (years) 7.9 (range
1–15), M = 8 F = 7.
doi:10.1371/journal.pone.0094010.t001
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housekeeping genes GAPDH and UBC using the DDCT method.
Viral RNA was quantified using a reference standard (Primer
Design, Southampton, UK).
Cytokine analysis
Protein secretion of IL-8, Interferon gamma-induced protein
(IP-10), and Granulocyte macrophage colony-stimulating factor
(GM-CSF) into cell-conditioned media was measured by ELISA
(R&D, Abingdon, United Kingdom), following the manufacturer’s
instructions.
Statistical analysis
Normality of distribution was assessed using the Shapiro Wilk
test (Sigmaplot) and parametric (ANOVA) or non parametric
(Friedman repeated measures ANOVA on Ranks) tests undertak-
en for within group comparisons, as appropriate to detect any
overall changes with different treatments. Where significant
differences were identified, pairwise tests (paired T-test (T-test)
or Wilcoxon signed rank test (Wilcoxon) respectively were used to
investigate between-treatment differences. To assess to possibility
of synergistic effects, the sum of cytokine release of single
treatments (Th2 and virus) and cytokine release observed in
combined treatment was compared using the same methodological
approaches. P,0.05 was considered statistically significant.
Whiskers on boxplots represent 5th-95th centile.
Results
Th2 cytokines enhance RV16-induced IP-10 release
Upregulation of IL-8 expression by IL-13 (10 ng/ml) and IL-4
(10 ng/ml) treatment was confirmed by ELISA. Initial experi-
ments showed cultures treated with IL-4, IL-13 or both cytokines
released significantly higher amounts of IL-8 than no treatment
(NT) controls (p,0.001, Figure 1A, n= 9) but there was no
difference between treatments. This demonstrates that the cells,
originating from subjects without asthma, are responsive to Th2
cytokines. The combination of IL-13 and IL-4 induced expression
of IL-8 (Figure 1B, p,0.05, n= 15) but not IP-10.
We next assessed the effect of Th2 cytokines on RV16-induced
inflammatory responses. pBECs were treated with Th2 cytokines,
or not, for 24 hours before infecting with RV16 (16106 TCID50
units/106 cells (MOI 1). Both IL-8 (p,0.01) and IP-10 p,0.01)
release were significantly stimulated by RV16 infection alone
(Figure 2A and 2B respectively). No induction of IL-8 or IP-10 was
observed with UV irradiated virus (UV), suggesting cytokine
induction to be a result of viral replication. The secretion of IL-8
and IP-10 protein was augmented in cultures pretreated with Th2
cytokines (Figure 2A: IL-8, p,0.05, 2B: IP-10, p,0.01). The
increase in virus-induced IP-10 expression was synergistic in the
presence of Th2 cytokines compared to the sum of the values of
single challenges (p,0.01), whilst the increase in IL-8 was additive.
We also investigated GM-CSF because of its involvement with
dendritic cell recruitment and maturation, linking innate and
adaptive immune responses. We saw no significant increase in
protein release in response to Th2 cytokines alone but up-
regulation of GM-CSF (p,0.05) was observed in response to virus
infection. The presence of RV16 and Th2 cytokines resulted in an
additive effect on GM-CSF release (p,0.01) compared to virus
alone (Figure 2C).
Viral replication is not moderated by Th2 cytokines
We hypothesised that the presence of Th2 cytokines favoured
viral replication, causing the observed increase in IL-8, IP-10 and
GM-CSF release. However, we did not see any differences in viral
copy number when cells were infected in the absence or presence
of the Th2 cytokines (Figure 3) (RV16 copy number (median
(range) = 2.06104 (2.26102–1.46105) versus 1.46104 (3.06102–
1.46105) n= 15, respectively). Viral titre (virus released into the
supernatant) was measured using TCID50 and again we could
detect no difference between cells pretreated in the absence or
presence of Th2 cytokines (RV16 titre (median (range)) =
2.86105 (2.86104–1.56106) versus 56105 (1.56104–8.96106)
n = 15, respectively). Absence of replicating virus in the UV
controls was confirmed using the same methods.
Major group RVs such as RV16 are reported to have less
cytotoxicity than minor group virus [20] and in keeping with this
we did not see cytopathic effects in our cultures at 24 hours (Figure
S1). We measured Lactate Dehydrogenase (LDH), an enzyme
found in the cytosol of cells and released into supernatant upon cell
damage or lysis. We did not detect a difference in LDH levels
between cells infected with virus in the presence of Th2 cytokine
compared to virus alone (data not shown).
We also examined expression of ICAM-1, the cellular receptor
for RV16. There was no detectable change in expression following
24hr Th2-cytokine treatment. (Figure S2). Together these data are
consistent with the view that the observed increases in cytokine
expression in the presence of Th2 cytokines is not a consequence
of increased entry of virus, or increased viral replication.
Inhibition of inflammatory pathways
The combined effects of Th2 cytokines and RV16 infection
produced different effects depending on the response being
Figure 1. Induction of IL-8 but not IP-10 in response to Th2
stimulation. ppBECs were treated for 24 hours with IL-13 (10 ng/ml)
and IL-4 (10 ng/ml) for 24 hours. Protein secretion in cell supernatant
was measured by ELISA (R&D). Statistical analysis 1A n= 9 ANOVA
P,0.05. 1B n= 15, Wilcoxon, p,0.05. NT-no treatment.
doi:10.1371/journal.pone.0094010.g001
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measured. IP-10 release was synergistic while IL-8 and GM-CSF
release were additive. One explanation could be that these
cytokines are stimulated by distinct signaling pathways. We
therefore repeated our experiments using inhibitors of PI3K
(LY294002) [21] and p38 MAPK (SB203580) pathways [22] and
also Dexamethasone [23]. LY294002 is being considered for
development as a cancer drug [24] and has potential in respiratory
disease. SB203580 was chosen since activation of p38 MAP
kinases occurs early in RV infection so participates in signalling
cascades controlling cellular responses to cytokines and stress [25].
Dexamethasone was chosen since it is used as an anti inflamma-
tory treatment for asthma and has been shown to inhibit IL-8 in
previous studies [26,27].
A significant change in virus-induced IL-8 and IP-10 protein
expression was observed in the presence of inhibitors, with or
without Th2 cytokines (ANOVA: IL-8 p= 0.001, IP-10 p= 0.04).
Dexamethasone significantly inhibited RV16-induced IL-8 release
both in the absence (p = 0.008) or presence (p= 0.03) of Th2
cytokines (Figure 4A). The potent inhibitory effect of dexameth-
asone on IL-8 release is in keeping with our previous observations
[28]. The PI3K inhibitor had only a modest inhibitory effect on
IL-8 release but significantly reduced RV16-induced IP-10
expression in the absence (p= 0.016) or presence (p = 0.017) of
Th2 cytokines (Figure 4B). Dexamethasone was much less effective
at inhibiting RV16-induced IP-10 than the PI3K inhibitor, and
the effect was reduced further in the presence of Th2 cytokines.
We saw no significant inhibitory effects on IL-8 or IP-10 with the
p38 MAPK inhibitor.
RV16-induced GM-CSF expression was almost completely
suppressed by dexamethasone both in the absence (p,0.05) or
presence (p,0.01) of Th2 cytokines (Figure 4C). Virus replication
and release were not altered by the presence of inhibitors in the
cultures (Figure S3). This suggests that the inhibitors were acting
on signal transduction pathways linked to cytokine expression and
was not a result of suppression of virus replication.
We show that RV-induced IP-10 release is synergistically
enhanced in the presence of Th2 cytokines, and that this effect can
be blocked by inhibition of the PI3K pathway.
Discussion
In this study, we used primary epithelial cells from a non-
asthmatic pediatric population and experimentally promoted a
Th2 environment using exogenous Th2 cytokines. We show that,
in undifferentiated pediatric bronchial epithelial cell cultures, Th2
cytokines do not increase entry or replication of virus but do
augment the release of inflammatory mediators following RV
infection.
The complexity of interactions between environment, host and
pathogen make it difficult to assess the contribution of individual
components of asthma or atopy but several attempts have been
made to tease apart these interactions [29–31]. For simplicity we
chose to use non-differentiated cultures to mimic the basal cells of
the pseudostratifed bronchial epithelium [32] with a combination
of both cytokines to more closely model in vivo conditions
[14,33,34]. It is known that these cells are exposed in asthmatic
bronchial epithelium due to epithelial damage and/or fragility
[35]. When we designed the study we did not collect data on atopy
since this would incur additional skin and blood tests which we felt
would be unreasonable in such a young cohort. We recognize that
this is a limitation of the study. Further, to our knowledge there are
no data comparing responses of very young children with older
teenagers. The wide age range used in this study was unavoidable
given the difficulty in recruiting pediatric subjects and we cannot
exclude age effects on the responses of the cells.
Our aim was to investigate whether Th2 cytokines, IL-13 and
IL-4, modulate the effects of RV infection in bronchial epithelial
monolayers. We confirmed previously reported RV-induced up-
regulation of inflammatory cytokines IL-8 and IP-10 observed in a
cell line [36] and in pBECs taken from adult subjects (Figure 2)
[28]. In the study by Wark et al rhinovirus induced IP-10 and IL-8
expression of pBECs from adult subjects with allergic asthma was
not significantly different to nonatopic healthy controls [28] and
this may also be true of pediatric cultures. To our knowledge a
similar comparison in a pediatric population has not been
performed and unfortunately samples were not readily available
for comparison in this study [19,37].
Using ppBECs from non asthmatic subjects we demonstrate
that infection in the presence of Th2 cytokines stimulated a
Figure 2. Synergistic increase in virus-induced IP-10 release in
the presence of Th2 cytokines. ppBECs were pretreated with IL-13 +
IL-4 or not for 24 hours prior to infection with RV16 at 16106 TCID50
units/106 cells (n = 15). Protein secretion in cell culture supernatants was
measured after 24 h using ELISA (R&D). Statistical analysis used ANOVA
for within group comparison, followed by 2A) IL-8, T-test, 2B) IP-10,
Wilcoxon and 2C) GM-CSF, Wilcoxon.*P,0.05 **P,0.01. NT-no treat-
ment.
doi:10.1371/journal.pone.0094010.g002
Virus Infection and Th2 Cytokines in Asthma
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Figure 3. Replication of RV was not modified in the presence of Th2 cytokines. ppBECs were pretreated with IL-13 + IL-4 or not for 24 hours
prior to infection with RV16 at 16106 TCID50 units/10
6 cells. Viral RNA was quantified and expressed as copy number relative to known standards
(n = 15). Viral release into the supernatant was measured using TCID50 assay (n = 15).
doi:10.1371/journal.pone.0094010.g003
Figure 4. Inhibition of inflammatory pathways suppress virus- induced cytokines. ppBECs were pretreated with IL-13 + IL-4 (clear bars) or
not (shaded bars) for 24 hours prior to infection with RV16 (n = 8). Inhibitors were added 30 minutes prior to infection. Protein secretion in cell
supernatant was measured using ELISA (R&D). Statistical analysis used ANOVA (*p,0.05) followed by 4A) IL-8, Wilcoxon (absence) or T-test (presence)
of Th2 cytokines, 4B IP-10 Wilcoxon (absence) or T-test (presence) of Th2 cytokines and 4C) GM-CSF, T-test. Data were normalized relative to no
treatment and cytokine only controls. Total inhibition is shown as 100% and no inhibition as ,1%.
doi:10.1371/journal.pone.0094010.g004
Virus Infection and Th2 Cytokines in Asthma
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significant increase in IL-8, IP-10 and GM-CSF release. This
appeared to be unrelated to a direct effect of the Th2 cytokines on
viral replication, since no significant increase in viral RNA
expression or viral titre was observed. Most importantly, the effect
of RV infection and Th2 cytokines on IP-10 release was synergistic
and this effect could be inhibited by blocking the activity of PI3K.
Further investigations are important to ascertain the basis of this
enhancement, but this is beyond the scope of the present study.
It has been reported that expression of ICAM-1, the cellular
receptor for major group RVs such as RV16 is up-regulated by IL-
4 and IL-13 following 24 hour incubation [14,34]. Such an
increase in ICAM-1 would be expected to make the cells more
vulnerable to RV16 infection, with increased binding and entry of
virus into the cells leading to enhanced viral replication. We saw
variability in the level of ICAM-1 expression in cultures taken
from a small subset of 6 children (ages 1–15) used in the study but
we did not see any significant up-regulation of ICAM-1 expression
following 24 hr stimulation with Th2 cytokines. Whilst these
results differ from some previous publications, this may be
explained by the different models used [14,34].
We did not observe differences in cytopathic effects or LDH
release in our cultures at 24 hours (Figure S1) suggesting that the
increases in IL-8, IP-10 and GM-CSF were not caused by
increased cell death or enhanced viral replication. This supports
the findings of Wood et al who performed a study in an asthmatic
population presenting to hospital with acute asthma exacerbation.
They reported that expression of IP-10 is maintained when non-
replicating virus is present (ie. viral persistence) and concluded that
cellular inflammation caused by viral infection rather than viral
replication itself was responsible for the clinical manifestations of a
viral induced exacerbation of asthma [38].
We have previously reported that IP-10 expression is much less
sensitive to suppression by dexamethasone and that IP-10 levels in
serum remain elevated in subjects admitted to the emergency
room with a virus-induced asthma exacerbation [28]. We found
that dexamethasone was a poor inhibitor of IP-10 release from
RV16 infected pBECs but confirmed potent inhibition of IL-8
release, in keeping with other studies [26,27].
We show that IP-10 release can be blocked by inhibition of
PI3K. IP-10 expression is known to be corticosteroid refractory,
and our finding that inhibition of PI3K in pBECs potently
suppresses IP-10 expression may have therapeutic implications,
having the potential to attenuate IP-10 and bring inflammation
under control where dexamethasone has no effect. PI3Ks play
important roles in tumorigenesis, so there is considerable interest
in development of PI3K inhibitors as cancer potential therapeutic
agents [39]. LY294002 acts as a competitive ATP binder [40] and
has significant in vivo antitumor efficacy [24]. Recent studies
elucidating the crystal structure of LY294002 provides a basis for
development of its therapeutic potential [41].
In conclusion we show that Th2 cytokines, IL-13 and IL-4,
synergistically enhance release of RV-induced IP-10, independent
of replicating virus. This release can be inhibited by blocking the
PI3K pathway.
Supporting Information
Figure S1 Phenotypes of cell cultures under the differ-
ent conditions. pBECs were pretreated with IL-13 + IL-4 or
SFM for 24 hours prior to infection with RV16 at 16106 TCID50
units/106 cells (n = 15). After 1 hr, infection medium was removed
and the cells washed with PBS. Starvation medium was replaced
+/2 cytokines. No differences were seen between the different
treatments. Pictures are representative of all the cultures.
(TIF)
Figure S2 ICAM-1 receptor expression was not altered
following 24hr stimulus with Th2 cytokines. pPBECs were
treated for 24 hours with IL-13 10 ng/ml, IL-4 10 ng/ml or both.
ICAM-1 expression was assessed using flow cytometry. Data are
plotted as ICAM-1 expression relative to isotype control, or as
percent positive cells n = 6. No treatment controls were included
for comparison.
(TIF)
Figure S3 Replication of virus was not moderated by
inhibitors. pBECs were pretreated with IL-13 + IL-4 or SFM for
24 hours prior to infection with RV16 at 16106 TCID50 units/10
6
cells (n = 8). Inhibitors were added 30 minutes before infection.
After 1 hr, infection medium was removed and the cells washed
with PBS. Starvation medium was replaced +/2 cytokines and/or
inhibitors. Viral release into cell culture supernatants was
measured using TCID50 assay. Expression of viral RNA was
quantified using RT-qPCR and expressed as copy number relative
to known standards.
(TIF)
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